Shares of Absci Corp (NASDAQ:ABSI) have been given an average rating of “Hold” by the six ratings firms that are covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $30.00.
A number of analysts have issued reports on ABSI shares. Cowen started coverage on Absci in a research note on Monday, August 16th. They issued a “market perform” rating on the stock. Bank of America began coverage on Absci in a research note on Monday, August 16th. They set a “neutral” rating and a $26.00 price objective for the company. Credit Suisse Group initiated coverage on Absci in a report on Monday, August 16th. They set an “outperform” rating and a $40.00 target price on the stock. UBS Group initiated coverage on Absci in a research report on Monday, August 16th. They set a “neutral” rating and a $26.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on Absci in a research report on Monday, August 16th. They set a “hold” rating and a $28.00 price target on the stock.
ABSI stock traded up $0.18 on Friday, reaching $14.40. The company’s stock had a trading volume of 2,123 shares, compared to its average volume of 345,017. Absci has a 12-month low of $13.68 and a 12-month high of $31.53.
In other news, Director Karen K. Mcginnis bought 15,000 shares of Absci stock in a transaction dated Monday, July 26th. The stock was acquired at an average cost of $16.00 per share, with a total value of $240,000.00. Following the acquisition, the director now owns 15,000 shares of the company’s stock, valued at $240,000. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, General Counsel Sarah Korman purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 26th. The stock was bought at an average price of $16.00 per share, for a total transaction of $160,000.00. Following the transaction, the general counsel now directly owns 10,000 shares in the company, valued at $160,000. The disclosure for this purchase can be found here. Insiders have acquired a total of 26,600 shares of company stock valued at $425,600 over the last ninety days.
Absci Corporation is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. The company’s Creation(TM) Platform involved in discovery of novel biotherapeutic drug candidates and generation of the cell lines to manufacture them in a single efficient process.
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.